Drug Profile
Ricolinostat - Regenacy Pharmaceuticals
Alternative Names: ACY-1215; ACY-63; RocilinostatLatest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute; Harvard University
- Developer Columbia University; Dana-Farber Cancer Institute; Massachusetts General Hospital; Regenacy Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple myeloma
- Phase I/II Lymphoma
- Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Preclinical Malignant melanoma; Peripheral nervous system diseases
- No development reported Breast cancer; Chronic lymphocytic leukaemia
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 07 Nov 2019 Phase-I development is ongoing for Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater), Peritoneal cancer (Combination therapy, Recurrent, Second-line therapy or greater) and Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (NCT02661815)
- 07 Nov 2019 Celgene and Dana Farber Cancer Institute terminate a phase Ib trial in Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater), Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) and Peritoneal cancer (Combination therapy, Recurrent, Second-line therapy or greater) (owing to company reluctance for further accrual) in USA (PO) (NCT02661815)